| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PLoSO..1162903P |
| P356 | DOI | 10.1371/JOURNAL.PONE.0162903 |
| P932 | PMC publication ID | 5033451 |
| P698 | PubMed publication ID | 27658209 |
| P50 | author | Niels H Chavannes | Q55113595 |
| Richard Russell | Q57326870 | ||
| Rafael Mares | Q83415307 | ||
| David Price | Q37830471 | ||
| P2093 | author name string | John Haughney | |
| Jeffrey W Stephens | |||
| Janwillem W H Kocks | |||
| Helga Mikkelsen | |||
| Anne Burden | |||
| Derek Skinner | |||
| Cherlyn Ding | |||
| Richard Brice | |||
| P2860 | cites work | A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness | Q21135236 |
| Diabetes mellitus among outpatients with COPD attending a university hospital. | Q50698868 | ||
| Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. | Q51728540 | ||
| Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia | Q80076108 | ||
| Switching to CFC-free beclometasone for asthma | Q81399390 | ||
| Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 | ||
| A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease | Q26801661 | ||
| Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q28111913 | ||
| Chronic obstructive pulmonary disease | Q28259151 | ||
| Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease | Q29618681 | ||
| Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada | Q30278856 | ||
| Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus | Q30426632 | ||
| Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns | Q34134884 | ||
| Impact of preventing exacerbations on deterioration of health status in COPD. | Q34548347 | ||
| The effect of an inhaled corticosteroid on glucose control in type 2 diabetes | Q34604971 | ||
| The association of inhaled corticosteroid use with serum glucose concentration in a large cohort | Q34606671 | ||
| Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression | Q34623808 | ||
| Obesity and the lung: 5. Obesity and COPD. | Q34884346 | ||
| Systemic effects of inhaled corticosteroids: an overview | Q35056155 | ||
| Effect of inhaled corticosteroids on glycemic status | Q35056185 | ||
| Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study | Q35138038 | ||
| Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony | Q36402823 | ||
| Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS) | Q36883006 | ||
| Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications | Q37193551 | ||
| Inhaled corticosteroids in COPD and the risk of serious pneumonia | Q37267655 | ||
| What the pulmonary specialist should know about the new inhalation therapies | Q37839525 | ||
| Meta-review: adverse effects of inhaled corticosteroids relevant to older patients | Q38198574 | ||
| Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids? | Q38571581 | ||
| The distribution of COPD in UK general practice using the new GOLD classification. | Q39323164 | ||
| Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. | Q43849257 | ||
| How far is real life from COPD therapy guidelines? An Italian observational study | Q43850539 | ||
| Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations | Q44304476 | ||
| Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease | Q44304480 | ||
| The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide | Q46966092 | ||
| Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study | Q47227282 | ||
| Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease | Q48487432 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | e0162903 | |
| P577 | publication date | 2016-09-22 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study | |
| P478 | volume | 11 |
| Q64082084 | Age- and sex-specific prevalence of chronic comorbidity in adult patients with asthma: A real-life study |
| Q64097129 | Association between full monitoring of biomedical and lifestyle target indicators and HbA level in primary type 2 diabetes care: an observational cohort study (ELZHA-cohort 1) |
| Q92731751 | COPD patients prescribed inhaled corticosteroid in general practice: Based on disease characteristics according to guidelines? |
| Q95266863 | Comparison of Characteristics Between ICS-Treated COPD Patients and ICS-Treated COPD Patients with Concomitant Asthma: A Study in Primary Care |
| Q90083689 | Defining severe obstructive lung disease in the biologic era: an endotype-based approach |
| Q90668963 | Do Benefits Outweigh Risks for Corticosteroid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease in People with Diabetes Mellitus? |
| Q100750130 | Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients |
| Q90974949 | Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study |
| Q50084941 | Neutrophil to lymphocyte ratio as a predictor for type 2 diabetes mellitus in patients with chronic obstructive pulmonary disease: a cohort study of 404 cases |
| Q92044310 | Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies |
| Q38598993 | The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study |
| Q58694610 | Toward effective prescription of inhaled corticosteroids in chronic airway disease |
| Q47718704 | Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine |
Search more.